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Abstract
Staphylococcus aureus is a major cause of nosocomial and community-acquired infections for which a vaccine is greatly
desired. Antigens found on the S. aureus outer surface include the capsular polysaccharides (CP) of serotype 5 (CP5) or 8
(CP8) and/or a second antigen, a b-(1R6)-polymer of N-acetyl-D-glucosamine (PNAG). Antibodies specific for either CP or
PNAG antigens have excellent in vitro opsonic killing activity (OPKA), but when mixed together have potent interference in
OPKA and murine protection. To ascertain if this interference could be abrogated by using a synthetic non-acetylated
oligosaccharide fragment of PNAG, 9GlcNH2, in place of chemically partially deacetylated PNAG, three conjugate vaccines
consisting of 9GlcNH2 conjugated to a non-toxic mutant of alpha-hemolysin (Hla H35L), CP5 conjugated to clumping factor
B (ClfB), or CP8 conjugated to iron-surface determinant B (IsdB) were used separately to immunize rabbits. Opsonic
antibodies mediating killing of multiple S. aureus strains were elicited for all three vaccines and showed carbohydrate
antigen-specific reductions in the tissue bacterial burdens in animal models of S. aureus skin abscesses, pneumonia, and
nasal colonization. Carrier-protein specific immunity was also shown to be effective in reducing bacterial levels in infected
lungs and in nasal colonization. However, use of synthetic 9GlcNH2 to induce antibody to PNAG did not overcome the
interference in OPKA engendered when these were combined with antibody to either CP5 or CP8. Whereas each individual
vaccine showed efficacy, combining antisera to CP antigens and PNAG still abrogated individual OPKA activities, indicating
difficulty in achieving a multi-valent vaccine targeting both the CP and PNAG antigens.
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Introduction
Effective vaccination against infections due to Staphylococcus
aureus, one of the most common causes of both community-
acquired and life-threatening nosocomial infections [1,2] has a
clear and high priority. Despite promising preclinical data
obtained from protection studies in animals, vaccines that targeted
S. aureus capsular polysaccharides (CP) type 5 (CP5) and type 8
(CP8) antigens [3], the iron-surface determinant B (IsdB) protein
[4,5], a monoclonal antibody to lipoteichoic acid, as well as an
immune globulin selected from plasma donors with high titers of
antibody to clumping factor A (ClfA) [6], all failed to protect
patients against staphylococcal infections in phase III clinical trials
[3,7,8].
One major issue in vaccine research for S. aureus infections is a
lack of knowledge as to the target antigens and immune effectors
that optimally protect humans against this pathogen. Thus,
current attempts to develop vaccines are essentially empiric,
utilizing examples from successful approaches for other pathogens,
animal protection studies, and in vitro correlates such as opsonic
killing or interference with binding of bacteria to target proteins.
As a result of this approach, and given the multiple and redundant
virulence factors of S. aureus, it might be logical to deduce that an
effective vaccine may need to be composed of multiple bacterial
components, potentially incorporating surface polysaccharides,
toxoids, and cell-wall associated proteins.
Using empiric approaches derived from protective efficacy
observed in animal studies of S. aureus infection, candidates for
inclusion in a multi-component staphylococcal vaccine encompass
the polysaccharide antigens poly-N-acetyl glucosamine (PNAG),
expressed by .95% of strains [9], and CP5 and CP8, produced by
,75% of strains. A key characteristic of the PNAG antigen, in
terms of its vaccine potential, is that the immune response needed
to elicit optimal opsonic and protective antibody is affected by the
N-acetyl groups on the glucosamine constituents [10]. When
native PNAG from S. aureus (.90% acetylated) was chemically
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glycoform (dPNAG) elicited opsonic and protective antibody
against S. aureus [10] as well as other PNAG-producing pathogens
[11,12,13]. In contrast, antibody specific to epitopes incorporating
the acetylated glucosamine monomers on PNAG were poorly
opsonic and not protective [10]. Notably, most humans (.95%)
have high titers of natural antibody directed to the acetylated
epitopes of native PNAG, and this antibody is poorly opsonic and
not protective in animal models. Some, but not all, human
infections with S. aureus induce opsonic antibodies to dPNAG
[14,15], and ,3% of normal humans have natural dPNAG-
specific opsonic antibody (unpublished finding). The validity of
raising antibody to the deacetylated glycoform of PNAG to
produce protective antibody was strongly validated in work that
used a synthetic oligosaccharide composed of nine b-1-6-linked
monomers of glucosamine (9GlcNH2) conjugated to tetanus toxoid
(TT) as a vaccine. This glycoform engendered opsonic and
protective antibody whereas the fully acetylated synthetic glyco-
form conjugated to TT, 9GlcNAc-TT, did not induce protective
immunity. However, whether the antibodies elicited to the
synthetic oligosaccharide would also interact in a negative manner
with antibodies to CP5 or CP8 was not investigated.
Additional candidate components for a multi-valent vaccine for
S. aureus include two cell wall-anchored proteins, IsdB and ClfB,
both of which have shown protective efficacy in animals [4,16].
Although a clinical trial of the IsdB antigen as a single vaccine
component to prevent post-surgical wound infections following
cardiothoracic surgery was terminated [7], IsdB might nonetheless
contribute to a multi-component vaccine, as immunization with
this antigen has protected mice against lethality and renal abscess
formation [4,17]. A ClfB vaccine was protective against nasal
colonization [18]. Another component under clinical development
is alpha-hemolysin (Hla), a secreted S. aureus toxin that causes
pore formation in eukaryotic cells. Immunization with a geneti-
cally engineered non-toxic Hla (H35L) protein [19] protected
against lethality and reduced infection severity from sublethal
doses of S. aureus in models of systemic infection [20] and
pneumonia [21], although trials of Hla-based vaccines in humans
dating back to the 1930’s have been of uncertain efficacy [22].
Overall, using the animal protection data to make judgments as
to potential vaccine components that might be incorporated into a
comprehensive, multi-component vaccine for S. aureus, wherein
some additive or synergistic efficacy might be achieved, we have
prepared 3 different conjugate vaccines using the polysaccharide
antigens 9GlcNH2 (for PNAG), CP5 and CP8, and 3 proteins,
Hla-H35L, IsdB and ClfB as carriers, wherein 9GlcNH2 was
conjugated to Hla-H35L, CP5 was conjugated to ClfB and CP8 to
IsdB, to evaluate immunogenicity in animals, in vitro activities
including opsonic killing, toxin neutralization and inhibition of
binding to human fibrinogen by ClfB along with protection in
mouse models of S. aureus skin abscess formation, pneumonia,
and nasal colonization.
Materials and Methods
Bacterial strains used
S. aureus isolates used were CP8 strain MN8 [23], CP5 strain
Newman [24], and nontypable (NT) USA 300 MRSA strain LAC
[25]. Isogenic variants lacking cap, ica, clfA, clfB, and isdB have
been previously described [10,26,27,28,29,30,31,32]. Mutants
were constructed in spontaneous streptomycin-resistant (Sm
r)
isolates of wild-type S. aureus strains Newman [33] that were
selected on tryptic soy agar (TSA) plates containing 0.5 mg/ml
streptomycin as described before [16].
Carbohydrate components of the vaccines
Purified CP5 and CP8 were prepared as described [32].
Synthetic 9GlcNH2-S-S was produced as described [34].
Construction of recombinant rHla-H35L and rClfB
expression vectors
To generate plasmid pHla, hla was PCR amplified from S.
aureus strain DU1090 (pH35L) [19] with primers: 59-
CCCGGGCTCGAGAATGCCGCAGATTCTGATATTAA-
TATTAAAACC-39 and 59CCCGGGGATCCTTTAATTTGT-
CATTTCTTCTTTTTCCCAATCGATTTTATATCT-39.
To generate pClfB, clfB was amplified by PCR from S. aureus
strain Newman with primers 59-CCCGGGCTCGAGTCAGAA-
CAATCGAACGATACAACGCAATCT-39 and 59-
CCCGGGGGATCCAATCACCATCAGCACTTCCACCAC-
39. The primers for both targeted genes carried restriction sites for
BamHI and XhoI at the 59 and at the 39 ends restriction sites for
BamHI and XhoI, respectively. Amplified PCR fragments were
cloned into the expression vector pET16b (Novagen) digested with
BamHI and XhoI to yield pHla and pClfB and introduced into E.
coli TOP10 cells and subsequently transformed into E. coli
BL21(DE3).
Biologically active Hla was produced by Escherichia coli BL21
carrying the cloned gene in the vector pGEX 4TI [35], which was
kindly provided by Pyong Park, Children’s Hospital, Boston.
IsdB protein was produced by Escherichia coli TOP3 cells
carrying plasmid pQE30iisdB [36] which was kindly provided by
Prof. Tim Foster, Trinity College, Dublin.
Purification of recombinant proteins
Expression of genes for active Hla, non-toxic Hla-H35L, ClfB
and IsdB proteins was induced with 1 mM IPTG and the resultant
His-tagged proteins purified by Ni2+ affinity chromatography as
described previously [37] at the New England Research Center for
Excellence Biomolecule Production Core Laboratory. Purities
.95% by Coomassie-stained gels were achieved for all proteins
(Figure S1).
Preparation of conjugate vaccines
The synthetic oligosaccharide 9GlcNH2-S-S [34] (1.0 mg in
100 ml of 0.1 M sodium phosphate, 0.15 M NaCl, 10 mM EDTA,
pH 8.0) was treated with washed Tris (2-carboxyethyl) phosphine
hydrochloride (TCEP) disulfide reducing gel (200 ml of a 50%
slurry in water). After incubation on a rotor rack at 22–24uC for
45 min, SH-derivatized oligosaccharides were separated from the
gel by centrifugation, and the gel-immobilized TCEP was washed
with the same pH 8.0 buffer (36100 ml) and supernatants
combined.
To activate the carrier protein, Hla-H35L (2 mg) was diluted in
200 ml of 0.1 M sodium phosphate, 0.15 M NaCl, 10 mM EDTA,
pH 7.2 and a solution of N-hydroxysuccinimidyl-3- (bromoaceta-
mido) propionate (SBAP, 1.3 mg in 40 ml of DMSO) added and
incubated for 2 h at 22–24uC. Unreacted SBAP was removed
using a PD-10 column in 0.1 M sodium phosphate, 0.15 M NaCl,
10 mM EDTA, pH 8.0 buffer, and the eluate concentrated to
400 ml. The SH-activated oligosaccharide was immediately
combined with modified Hla-H35L protein (400 ml in pH 8.0
buffer), this mixture stirred 18–24 h at 22–24uC, then the
conjugate separated from uncoupled components by gel filtration
on Superose 6 prep-grade column. Fractions containing
9GlcNH2-Hla conjugate were pooled, concentrated and stored
frozen at 220uC.
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vaccines, CP5 or CP8 (2.88 mg in 0.05 M of sodium borate
pH=9.22) were treated with 1-cyano-4-dimethylaminopyridinium
solution (20 mg/ml) for 2 min at 20uC. The activated polysac-
charides were immediately combined with the carrier proteins,
ClfB or IsdB, respectively, (1.4 mg in sodium borate buffer,
pH=9.22), and the mixture stirred for 3 h at 20uC. The
conjugated CP and carrier proteins were separated from
uncoupled components by gel filtration on a Superose 6 prepgrade
column followed by removal of unconjugated CP by passing the
pooled fractions over a Ni-affinity column to retain the His-tagged
ClfB or IsdB while allowing unconjugated CP antigens to flow
through the column. Fractions containing CP5-ClfB and CP8-
IsdB conjugates were pooled, concentrated and frozen at 280u C.
Chemical analysis of the conjugate vaccines
9GlcNH2-Hla conjugate was analyzed for the oligosaccharide
content using a hexosamine assay [38] with the 9GlcNH2 free
oligosaccharide used as a standard. The CP5-ClfB and CP8-IsdB
conjugate vaccines were analyzed by ELISA using the corre-
sponding free, purified polysaccharide as standard. The proteins
were measured with a Bradford assay using BSA [39] as standard.
Antibody production using oligosaccharide conjugates
Rabbits were immunized subcutaneously with 10 mg (carbohy-
drate content) of the 9GlcNH2-Hla, CP5-ClfB and CP8-IsdB
conjugates twice, one week apart, with an equivalent volume of
incomplete Freund’s adjuvant. On the third week, rabbits were
immunized three times on alternate days with 5 mg (carbohydrate
content) of the conjugate given intravenously in saline. Blood was
taken two weeks after the final immunization and again two weeks
apart three times.
Antibody analysis by ELISA
Analysis of the antibody binding by ELISA to native PNAG was
done as previously described [10]. A regression analysis formula
was generated from linear values calculated by plotting the data as
the log10 serum dilution versus the OD405 value [40]. The antilog
of the dilution giving a value of zero was designated the serum
antibody titer.
Antibody analysis for opsonic killing activity
Antibody-dependent opsonic-killing (OPK) assays followed
published protocols [10,11,14] with some changes. In place of
neutrophils isolated from fresh human blood, we used an HL-60
cell line [41] that was kept at low passage (,3 months) and then
exchanged for freshly thawed aliquots. In accordance with the
protocol of Breitman et al, [42], maintenance of HL-60 cells was
performed in L-glutamine-containing RPMI 1640 medium (Gibco
Ltd., Carlsbad, Calif) supplemented with 15% heat-inactivated
fetal bovine serum and a standard antibiotic-antimycotic mixture.
The cells were kept in a 5% CO2 atmosphere at 37uC for four days
and were then harvested. Under these conditions, HL-60 cultures
can be maintained by diluting the cells with fresh medium to a
density of 10
5 viable cells/ml when the cell density reaches 10
6
cells/ml. N,N-dimethylformamide (DMF) (0.8%) was used to
induce granulocytic differentiation [41]. Optimal conditions for
differentiation into neutrophils with 100 mM DMF occurred over
a period of 5 days [43,44,45].
For the OPK assay, differentiated HL60 cells were washed in
Hanks’ Balanced Salt Solution (HBSS) lacking calcium chloride
and magnesium chloride and resuspended in HBSS with these two
divalent cations (HBSS
++) supplemented with 0.1% gelatin
(Sigma). Trypan blue staining was used to differentiate dead from
live leukocytes, and the final cell concentration adjusted to
2.5610
7 HL60 cells per ml. The complement source was rabbit
serum (Invitrogen) diluted 1:10 in HBSS
++ +1% Gelatin, which
was adsorbed at 4uC for 30 min with continual mixing with the
target S. aureus bacteria resuspended from a pellet containing
10
9 CFU. After adsorption, the complement solution was centri-
fuged and filter sterilized.
To achieve antigenic specificity in the OPK assay, polyclonal
sera were adsorbed with ,10
10 CFU/ml of either S. aureus
MN8Dica [10] to remove all antibodies to staphylococcal surface
antigens except those to PNAG, or S. aureus Newman Dcap5,
when testing OPKA against a CP5 strain, or S. aureus MN8
Dcap8, when testing OPKA against a CP8 strain. These latter two
adsorptions removed antibodies to all antigens except the
corresponding CP [30,31]. Additionally, a double gene deletion
in S. aureus MN8 lacking both the ica and cap8 loci (strain MN8
Dica+Dcap8) was used to adsorb antibodies to all antigens except
those to PNAG and CP8 that might be present in an immune
serum. USA 300 strain LAC, which is CP-negative, was used as a
target strain to detect the opsonic killing activity specific to ClfB
and IsdB cell-anchored surface proteins. To produce ClfB and
IsdB antibodies, CP5–ClfB polyclonal serum was adsorbed with
Newman DclfB strain and CP8-IsdB antiserum was adsorbed with
Newman DisdB supplemented with 2 mg of CP8 to mask the CP8
mediated OPKA. The test sera were adsorbed at 4uC for 30 min,
the bacterial cells removed by centrifugation, and the test sera
filter sterilized.
The bacterial strains to be evaluated for phagocyte-dependent
killing activity of antibody in immune sera were grown under
different conditions associated with expression of surface antigens.
For CP and PNAG antigen expression, S. aureus strains were
grown overnight in Columbia broth supplemented with 2% NaCl
(CSB). For testing of OPKA against the ClfB antigen, bacteria
were grown to early log phase in CSB, when antigen expression is
maximal. For testing the OPKA against IsdB, bacterial cells were
grown in low-iron medium needed to induce antigen expression,
which consisted of RPMI supplemented with 1% casamino acids.
In all cases, the culture was adjusted to an OD650 of 0.4 using
HBSS
+/+ +1% gelatin (,6610
8 CFU/ml), and then a further
1:300 dilution in HBSS
+/+ +1% gelatin made for use in the killing
assay to achieve a final bacterial concentration of ,2610
6 cfu/ml.
The OPK assay was performed by mixing 100 ml (each) of the
HL60 suspension, complement source, dilutions of test sera (made
in HBSS
+/+ +1% gelatin) and target bacteria (HL60 cell to
bacterial cfu ratio ,12.5:1). The reaction mixture was incubated
on a rotor rack at 37uC for 90 min; samples were taken at time
zero and after 90 min. A 10-fold dilution was made in TSB with
0.5% Tween to inhibit bacterial aggregation, and samples were
plated onto TSA plates. Tubes lacking any serum and tubes with
normal rabbit serum (NRS) were used as controls, as were tubes
containing serum and complement but lacking HL60 to control
for potential aggregation of bacteria by the antibody, which would
reduce the apparent CFU counts at the end of the assay. At the
concentrations of antisera used in the opsonic killing assay, there
was no reduction in CFU of .10% in samples lacking phagocytes
but containing antibody and complement, indicating little
agglutinating activity of the antibody to the target antigens.
The percentage of killing was calculated by determining the
ratio of the number of CFU surviving in the tubes with bacteria,
leukocytes, complement, and sera to the number of CFU surviving
in tubes containing normal rabbit sera, bacteria, complement, and
leukocytes. Killing rates of .30% were considered biologically
significant as this level represents the upper limit of the percentage
Multicomponent S. aureus Conjugate Vaccine
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normal sera lacking antibody to S. aureus, due to normal variation
in CFU counts in this assay.
Rabbit red blood cell (RRBC) hemolysis assay
Purified, active Hla at a final concentration of 6.25 nM was
incubated with 2 fold dilutions of either normal or immune rabbit
polyclonal serum raised against 9GlcNH2-Hla and a suspension of
12.5% rabbit red blood cells (RRBC) in PBS. After incubation for
1 h at 20uC, the samples were centrifuged at 2,000 rpm for
10 min. Supernatants were removed and the absorbance due to
released hemoglobin was measured at 475 nm. The percentage of
hemolysis was calculated using as a denominator the OD475 nm
reading from an equivalent number of RBC that had been lysed in
1% Triton X-100 to indicate 100% lysis. The 50% inhibition titer
was calculated using non-linear regression for sigmoidal curves
with variable slopes (PRISM 4 software).
Bacterial adherence to immobilized fibrinogen
Binding of S. aureus cells to immobilized fibrinogen was
performed as described previously [46]. Human fibrinogen was
diluted in PBS to 10 mg/ml, and 100 ml was used to coat 96-well
flat-bottomed ELISA plates incubated overnight at 4uC. The
plates were washed in PBS and blocked for 2 h at 37uC with 5%
BSA in PBS. A 20 ml culture of S. aureus Newman DclfA was
grown to an OD 600 of 0.5, centrifuged, washed in PBS and
resuspended to an OD600 nm of 1.0 in PBS. The cell suspension
was mixed with two fold dilutions of NRS or antibody to the CP5-
ClfB conjugate vaccine that were absorbed twice with S. aureus
Newman DclfB to leave only antibodies to the ClfB antigen in the
control and test sera. The bacteria and serum mixtures were added
to the fibrinogen-coated plates and incubated 2 h at 37uC. The
cells were washed in PBS and fixed by adding 100 ml of 25%
aqueous formaldehyde, and incubating at room temperature for
15 min. The plates were then washed gently, stained with crystal
violet, and washed again. The stained cells were resuspended in
5% acetic acid, and the OD570 nm read on an ELISA reader. The
50% inhibition of binding titer was calculated using non-linear
regression for sigmoidal curves with variable slopes (PRISM 4
software).
Murine pneumonia and skin infection models
Animal experiments were approved by the Harvard Medical
Area Institutional Animal Care and Use Committee. For mouse
lung infections, S. aureus strain Newman was grown at 37uCo n
Columbia salt agar for 18 h then inoculated into PBS to an OD600
nm of 0.4. Culture aliquots were centrifuged and washed in PBS,
and the bacterial cells suspended in PBS to achieve 2610
8 CFU
per 20 ml for Newman and 4610
8 CFU for PS80 and USA 300
LAC. FVB mice (Jackson Laboratory) 4–5 weeks old were
anesthetized and immunized with 10 ml of NRS or antisera to
9GlcNH2-Hla per nostril twenty-four and four h before challenge
with S. aureus. Twenty-four h after infection mice were sacrificed
and lungs were excised, weighed and homogenized for enumer-
ation of the lung bacterial load.
For evaluation of survival in a moribund/lethal infection model,
S. aureus strains LAC (USA 300) and LAC Dica were grown at
37uC on Columbia salt agar for 18 h then inoculated into TSB
supplemented with 1% glucose and grown to an OD600 nm of 1.0
with shaking at 250 rpm. Cultures were centrifuged and washed in
PBS, and the bacterial cells suspended in PBS to achieve
5610
8 CFU per 20 ml. Four weeks old FVB mice were
anesthetized by injection of ketamine and xylazine and immunized
with 10 ml of NRS or antisera to 9GlcNH2-Hla per nostril twenty-
four and four h before challenge with S. aureus. Survival was
monitored over time and moribund animals sacrificed and
counted as dead for purposes of data analysis using the Log-rank
test.
For mouse skin infections, S. aureus strains Newman, PS80 or
LAC were grown at 37uC on Columbia salt agar plates for 18 h
then suspended into PBS to an OD600 nm of 0.4. Culture aliquots
(10 ml for Newman and 1 ml of PS80 and LAC) were centrifuged
and re-suspended in 10 ml of a 1:1 ratio of PBS and Cytodex
micro-carrier beads, 67–80 mm (Sigma) as described [47]. To test
the protection of antibodies to ClfB against S. aureus LAC in the
skin infection model, bacteria were grown at 37uC in CSB to an
optical density at 600 nm of 0.5. 10 ml of culture was centrifuged
and re-suspended in 10 ml of 1:1 ratio of PBS and micro-carrier
beads.
Abscess formation was induced in mice by sc infection with S.
aureus. FVB mice (3–5 weeks old) were injected by the
intraperitoneal (IP) route with 0.3 ml of either NRS or immune
sera to 9GlcNH2-Hla, CP5-ClfB or CP8-IsdB 24 and 4 h prior to
S. aureus infection. One-hundred ml of the challenge bacteria was
injected into both flanks of a mouse and after 72 h the animals
euthanized and the abscesses removed, dissected, homogenized
and diluted in TSB for bacterial enumeration. For the analysis of
interaction between antibodies to PNAG and CP antigens, a mix
of antisera (100 ml of each) to 9GlcNH2-Hla, CP5-ClfB or CP8-
IsdB was injected IP 24 and 4 h and before challenge with S.
aureus. Controls received 300 ml of NRS.
Nasal colonization model
FVB mice 3–5 wks old were passively immunized IP with
0.3 ml of rabbit polyclonal antibodies raised to CP5-ClfB or with
NRS as the control 14 h prior to inoculation with 10
9 CFU of S.
aureus Newman resistant to streptomycin (Sm
r) as described [16].
The culture was grown at 37uC for 28 h on TSA and then
subcultured into 250 ml of TSB until an OD600 nm of 0.4 was
achieved. The culture was washed in PBS and suspended in 1 ml
of PBS (1610
9 CFU per 20 ml). Animals were challenged by the
IN route with 20 ml of S. aureus Sm
r Newman as described
previously [16,33]. The mice were euthanized 6 days after
bacterial challenge. The noses were excised and homogenized in
1 ml of TSB. The suspension was plated on 0.5 mg streptomycin/
ml to determine the number of S. aureus Newman Sm
r present per
nose.
Statistical analysis
Statistical analyses were performed using the Prism software.
The Mann-Whitney non-parametric two-tailed U test for two
sample comparisons was used to analyze paired data. Non-
parametric ANOVA was used for multi-group comparisons and
the Dunn Procedure for post-hoc pair-wise comparisons.
Results
Conjugate vaccine production
Recombinant, His-tagged non-toxic Hla (H35L), ClfB and IsdB
proteins were synthesized from DNA in the pET16b expression
vector (Novagen) using the T7 polymerase for transcription in E.
coli BL21 (DE3) cells (Figure S1). The His tag was left on the
proteins. These three recombinant proteins were then conjugated,
respectively, to 9GlcNH2, CP5, or CP8, as described in Materials
and Methods. Molecular sieve chromatography was performed to
separate the 9GlcNH2 oligosaccharide conjugated to the carrier
protein from the unconjugated oligosaccharide. However, it was
not possible to ascertain how much, if any, unconjugated protein
Multicomponent S. aureus Conjugate Vaccine
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between 9GlcNH2-Hla conjugated and unconjugated Hla carrier
protein was too small to reliably separate by size-exclusion
chromatography. For the CP-conjugated antigens, molecular sieve
chromatography was useful for separating conjugated and
unconjugated protein, and Ni-affinity columns were useful for
separating protein-conjugated CP from unconjugated CP.
Rabbit immune responses to 9GlcNH2-Hla, CP5-ClfB and
CP8-IsdB conjugate vaccines
Rabbits were immunized with each conjugate vaccine sepa-
rately so that the production of antibody to the six antigens could
be readily evaluated, individual as well as combined opsonic and/
or protective activity to specific antigens could be tested, the
potential for interference in antibody production or activity by
having antigens to both PNAG and CP in the same vaccine was
avoided, and sufficient amounts of consistent reagents for testing
immunity in multiple animals and different sites of infection would
be available. This approach does however, exclude any cellular
immune component that could contribute to protective immunity
following active vaccination.
Immunization with the 9GlcNH2-Hla conjugate elicited high
titers of antibody to native PNAG isolated from S. aureus and to
the rHla carrier protein (Fig. 1a). Thus, although these antibodies
were generated against epitopes lacking any acetates on the
glucosamine oligosaccharide constituents, they nonetheless bound
to the highly acetylated native form of the polysaccharide that is
the dominant glycoform on bacterial surfaces [34]. Antisera
against CP5-ClfB and CP8-IsdB had high antibody titers to native
polysaccharides CP5 and CP8 and to the carrier proteins ClfB and
IsdB (Figs. 1B and 1C).
In order to determine if, following conjugation with the
polysaccharides, the carrier proteins (Hla, ClfB and IsdB) retained
conformations associated with induction of antibodies recognizing
the native proteins, appropriate anti-toxic, anti-adhesive or
binding assays were performed with each individual antiserum.
We evaluated the antibodies to 9GlcNH2-Hla for neutralization
of the toxic activity of native Hla in a RRBC hemolysis assay.
Purified native Hla (6.25 nM) was incubated with two fold
dilutions of either NRS or antisera raised to 9GlcNH2-Hla and
12.5% RRBC. The dilution of serum (i.e., titer) needed to reduce
hemolysis by 50% was calculated by non-linear regression and was
found to be 4 (95% C.I. 2–13) for NRS and 216 (95% C.I. 28–
1648) for the antiserum raised to 9GlcNH2-Hla (P,0.05, Fig. 2a).
It has been previously reported that in the absence of ClfA,
which is the major S. aureus fibrinogen binding protein, S. aureus
can bind immobilized fibrinogen through a ClfB-dependent
mechanism [48]. To determine the functional activity of
antibodies raised to the CP5-ClfB conjugate, we tested the
inhibition of S. aureus adherence to fibrinogen using S. aureus
strain Newman lacking the clfA gene (DclfA), grown to an OD600
nm of 0.5. S. aureus DclfA was incubated with NRS or antisera
raised to CP5-ClfB, then added to fibrinogen-coated plates. The
NRS was unable to inhibit binding of S. aureus Newman DclfA by
.20% (titer ,10) while antibody to CP5-ClfB had a 50%
inhibitory titer of 118 (95% C.I. 56–210; P,0.05, Fig. 2b).
Iron surface determinant B (IsdB) plays a role in the acquisition
of heme iron through the binding to hemoglobin, and it is only
expressed under limited iron conditions, such as those that occur
during infection in mammalian hosts. The binding specificity of
antisera to CP8-IsdB antibodies was measured in an ELISA using
purified IsdB protein and either intact antisera or antisera
absorbed with S. aureus cells grown in low iron to induce IsdB
or high iron to repress IsdB. The intact antiserum and serum
absorbed with S. aureus MN8 grown in high iron both bound
comparably to purified IsdB (Fig. 2c), indicating no loss of
antibody from this absorption. However, antibody binding to IsdB
was markedly reduced when the antiserum was absorbed with S.
aureus MN8 grown in IsdB-inducing iron deficient conditions.
The calculated end-point titer of the serum after absorption with
S. aureus grown in low iron was significantly lower than that of the
unabsorbed antibodies or antibodies absorbed with S. aureus
grown in high iron (P,0.001, Fig. 2c), indicting antibodies raised
to CP8-IsdB recognized the native IsdB protein on the bacterial
surface.
Opsonic killing activity of the antisera
We next used polyclonal rabbit antibody raised to 9GlcNH2-
Hla, CP5-ClfB and CP8-IsdB to measure OPKA against S. aureus
strains Newman (CP5), PS80 (CP8) and USA 300 LAC (CP-) in
the presence of granulocytes (differentiated-HL60 human pro-
myelocytic cells) and rabbit complement (C9).
Animals immunized with the 9GlcNH2-Hla conjugate had
opsonically-active antibody that mediated killing of all three
PNAG-producing S. aureus strains Newman, PS80 and USA 300
Figure 1. Immune response of rabbits immunized with 9GlcNH2-Hla, CP5-ClfB and CP8 IsdB conjugate vaccines. (a) ELISA titers to
PNAG and recombinant Hla protein. (b) ELISA titers to CP5 and recombinant ClfB protein. (c) ELISA titers to CP8 and recombinant IsdB protein. Sera
were obtained from rabbits immunized with two subcutaneous doses of the conjugate vaccines equivalent to 10 mg of carbohydrate and three I.V.
doses corresponding to 7.5 mg of carbohydrate.
doi:10.1371/journal.pone.0046648.g001
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experience, has found that sera diluted 1:10 with PNAG-specific
OPKA killing of ,30% do not mediate protection in experimental
animal infections. The rabbit antisera deemed to have a positive
OPKA all showed antigen-specific bacterial killing .35% in a
1:20 serum dilution that was reduced to ,30% when sera were
diluted from 1:80 to 1:640, but for clarity we are only showing the
activity in the 1:20 serum dilutions (Fig. 3a). In the OPKA using
cells grown to stationary phase in CSB, which promotes CP
expression, the antibodies raised to CP5-ClfB showed killing
activity against S. aureus CP5 strain Newman but not against CP8
strain PS80 or CP
2 USA 300 LAC (Fig. 3a). Similarly, antibodies
raised to CP8-IsdB showed killing activity against S. aureus CP8
strain PS80 but not against CP5 strain Newman although a low
opsonic activity was found against CP- USA 300 LAC (21%). As
this could be due to antibody to IsdB, we next tested the OPKA of
the antiserum to CP8-IsdB following absorption of this serum with
S. aureus Newman DisdB to remove antibody to CP5 but retain
antibody to IsdB. For this assay we also grew the target bacterial
cells in a low-iron medium to enhance IsdB production. Here we
found almost as much OPKA in this absorbed serum against CP
2
strain LAC as there was in the unabsorbed serum raised to CP8-
IsdB. Similarly, a low level of killing of S. aureus Newman was
achieved with this antiserum, but not against strain PS80,
indicating that antibody to IsdB can mediate a modest amount
of OPKA against some S. aureus strains.
We also found the antiserum raised to CP5-ClfB, following
absorption with S. aureus Newman DclfB to remove antibody to
CP5, still had high killing activity (53%) against S. aureus strain
CP5 Newman grown to early log phase (Fig. 3a) but not against
PS80 or LAC (#20% killing, not considered significant). In early
log phase CP antigen production is low to absent [49], indicating
that for strain Newman, depending on the phase of growth,
antibody to either CP5 or ClfB can mediate OPK. Presumably the
low level of killing of strains LAC and PS80 by antibody to ClfB
reflects either poor expression of this antigen by these strains or
perhaps other factors made by these strains that interfere with
OPK mediate by antibody to ClfB. As with antibody to IsdB,
OPK of different S. aureus strains is variable when using antibody
to ClfB.
Interference of opsonic killing mediated by mixtures of
antibody to CP and PNAG antigens
Protective antibodies to both PNAG and S. aureus CP antigens
must have in vitro OPKA to mediate in vivo protection in
experimental models [10,14,15,49]. Our group has previously
shown that OPK of antibody induced in different rabbits by
conjugate vaccines specific to either CP or PNAG antigens is high,
but when mixed together they interfere with each other’s OPKA
due to a charge-based idiotype-anti-idiotype binding of the Fab
regions of these antibodies [15]. This also abrogates the protective
activity in skin infection and bacteremia models when the
individually protective antibodies are mixed together [15].
However, these prior results were generated using a chemically
deacetylated glycoform of native PNAG wherein about 15% of the
glucosamine residues remained acetylated. Moreover, tetanus
toxoid was used as the carrier protein for all three of the
carbohydrate antigens. To ascertain if using the fully non-
acetylated synthetic glycoform of PNAG, 9GlcNH2 along with
conjugating each carbohydrate to distinct carrier proteins as
vaccines could alter the induction of interfering antibodies, we
next mixed together the polyclonal rabbit antisera raised to CP5-
ClfB or CP8-IsdB with antibody to 9GlcNH2-Hla to determine if
interference in OPKA against S. aureus strains Newman and PS80
still occurred. A 1:20 dilution of rabbit antisera raised to
9GlcNH2-Hla showed antigen-specific OPKA .50% (Fig. 3b)
that was lost when this serum was mixed with 1:10 dilutions of
antisera to either CP5-ClfB or CP8-IsdB (Fig. 3b). Interference
disappeared as decreasing amounts of the antiserum to the CP
Figure 2. Effect of antisera to the carrier proteins Hla, ClfB and
IsdB on their biological activities. (a) Rabbit antisera raised to
9GlcNH2-Hla inhibited lysis of rabbit red blood cells (RRBC) due to S.
aureus hemolysin A. Percent hemolysis was calculated using as the
denominator the haemoglobin absorbance at 475 nm obtained
following lysis of control RBC in 1% Triton X-100. Lack of overlap in
the 95% C.I. between the 50% lysis titers indicates difference significant
at P,0.05. Bars represent mean of triplicates. (b) Inhibition of binding of
S. aureus Newman DclfA due to antibody raised to CP5-ClfB to
immobilized fibrinogen. Percent inhibition of binding was calculated
using as the denominator the OD650 nm values obtained in the control
with no serum. Lack of overlap in the 95% C.I. between the 50% lysis
inhibition titers indicates difference significant at P,0.05. Lines
represent mean of triplicates. (c) ELISA titers to purified IsdB protein
in intact antisera or antisera absorbed with S. aureus cells grown in an
iron depleted medium to induce IsdB, or in an iron-replete medium to
repress IsdB synthesis. Lines represent mean of duplicates.
doi:10.1371/journal.pone.0046648.g002
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antibody to 9GlcNH2-Hla was mixed with antibody to CP8-IsdB
was stronger than when mixed with antibody to CP5-ClfB, a
phenomenon we noted previously wherein antibody to CP8 gives
rise to stronger interference in OPK than does antibody to CP5
[15]. Thus the use of the synthetic oligosaccharide to PNAG and
distinct carrier proteins did not overcome the interference in
OPKA found when antibodies to this antigen were mixed with
antibodies to S. aureus CP antigens.
Passive immunization with antibody to 9GlcNH2-Hla
protects mice from S. aureus pneumonia
Several reports over the years [20,21] described that transfer of
Hla-specific antibodies protects naı ¨ve animals against S. aureus
lethality and lung infection. To examine the ability of antibody to
9GlcNH2-Hla to prevent pneumonia induced by S. aureus grown
to either the logarithmic or stationary phases, we passively
immunized 3–5 week old FVB mice with 20 ml of either NRS or
rabbit antibody to 9GlcNH2-Hla via the intranasal route (i.n.)
route 24 h and 4 h before i.n. challenge with 2610
8 CFU of S.
aureus Newman. Animals were sacrificed 24 h later and lungs
removed and bacterial loads determined. Compared to the NRS
control, passive immunization with 9GlcNH2-Hla antibodies
caused a significant reduction in the staphylococcal load for
animals challenged with S. aureus strain Newman strain grown to
either the logarithmic (P=0.015) (not shown) or stationary phases
(P,0.0001) (Fig. 4 A), with a greater effect seen when the
organisms grown to stationary phase were used for challenge.
Animals challenged with 4610
8 CFU of S. aureus PS80 or USA
300 strain LAC in stationary phase also had a reduction of CFU
recovered from the lungs in the immune serum immunized groups
compared to the NRS groups (P=0.016 and P=0.036, respec-
tively).
To determine the contribution of the antibody to the PNAG
antigen or the Hla hemolysin in reducing bacterial counts during
S. aureus lung infection, we challenged 10 FVB mice passively given
20 ml of either NRS or antibody to 9GlcNH2-Hla with
4610
8 CFU of S. aureus USA 300 strain LAC unable to make
PNAG (Dica) grown to stationary phase. Animals were sacrificed
24 h later and lungs removed and bacterial loads determined.
Compared to the NRS control, passive immunization with
9GlcNH2-Hla antibodies did not show a significant reduction in
the CFU recovered from the lungs (data not shown), suggesting
that the Hla-antibodies are not involved in reducing S. aureus
bacterial counts in the lungs.
As antibodies to Hla might augment overall survival from S.
aureus lung infection without reducing bacterial levels, we passively
transferred antibody to 9GlcNH2-Hla or NRS to mice 24 h and
4 h before i.n. challenge with a higher, lethal dose of 6610
8 CFU
of S. aureus USA300 LAC or USA 300 LAC Dica strains grown to
logarithmic phase. Survival (moribund or lethal) over the next
120 h was monitored (Fig. 4B). Animals challenged with USA 300
strain LAC had 100% survival if given antibody to 9GlcNH2-Hla
Figure 3. Opsonic killing activity in rabbit sera raised to 9GlcNH2-Hla, CP5-ClfB and CP8-IsdB conjugate vaccines. (A) Killing at a serum
dilution of 1:20 of S. aureus strains USA 300 LAC, PS80 and Newman with antisera raised to 9GlcNH2-Hla, CP5-ClfB and CP8-IsdB. Sera were absorbed
for antigenic specificity as follows: antisera to CP8-IsdB were absorbed with strain Newman DisdB grown to stationary phase in RPMI medium with 1%
casamino acids to make the serum specific to IsdB; antisera to CP5-ClfB were absorbed with strain Newman DclfB grown to log phase in CSB to make
the serum specific to ClfB. (B). Opsonic killing of S. aureus strains PS80 and Newman when one antiserum was held constant (CP5-ClfB or CP8-IsdB)
and the second one (9GlcNH2-Hla) diluted as indicated. Sera were made antigen-specific by absorption as indicated on figure. Bars represent means
of triplicate samples, and the percent S. aureus killed was compared to normal rabbit serum. Controls lacking complement or PMN had ,10% OPKA
(not shown).
doi:10.1371/journal.pone.0046648.g003
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protection (70%) was achieved in mice infected with S. aureus strain
USA 300 LAC Dica that had been given antibody to 9GlcNH2-Hla
where all of the animals given NRS died within 48 h following
challenge (P,0.0001). These data suggested that the combination
of antibody to both PNAG and Hla had a somewhat better ability
to protect mice against pneumonic death than did antibody to Hla
alone, which would have been the effective activity in mice
challenged with PNAG-negative S. aureus LAC Dica.
Protective efficacy against S. aureus in a murine skin
abscess model
In a murine model of skin abscesses elicited by inoculating the
bacteria subcutaneously along with small (60–87 mm) dextran
beads [47], IP injection of 300 ml of immune sera against
9GlcNH2-Hla 24 h and 4 h prior to infection resulted in
significant reductions in the bacterial CFU/abscess produced by
S. aureus strain Newman (P=0.0011), PS80 (P=0.0007), or LAC
(P=0.0003) when compared with animals given NRS (Fig. 5a).
Antibodies to CP5-ClfB reduced the mean CFU/abscess
recovered from mice challenged with CP5 strain Newman
(P=0.015) compared to the mice given NRS but did not reduce
bacterial burdens when the animals were infected with a CP
2
strain LAC (P=0.38) (Fig. 5b), suggesting antibody to ClfB was
not providing much protection is this setting.
The CP8-IsdB antiserum significantly reduced the CFU/abscess
formed by CP8 strain PS80 (P=0.04) (Fig. 5c), as well as those
formed by S. aureus strains Newman (CP5) or LAC (CP
2)
(P=0.0148 and P=0.0019, respectively) (Fig. 5c). These findings
suggest that not only are the antibodies to CP8 protective against
S. aureus skin infections caused by CP8 strains, as previously
shown [15], but also antibodies to IsdB have protective efficacy in
this murine skin abscess model.
Since our in vitro OPKA showed that in spite of use of the
9GlcNH2 glycoform to induce antibody to PNAG, the antibodies
to the different surface CP and PNAG polysaccharides interfered
with each other’s functional activity, we sought to determine if this
interference affected the in vivo protection apparently mediated by
antibody to IsdB. Thus, we passively immunized mice with
antibodies to 9GlcNH2-Hla, CP5-ClfB or CP8-IsdB that were
mixed together. In this setting the combination of antibodies raised
against the three conjugate vaccines still significantly reduced the
bacterial counts in abscess of mice challenged with either S. aureus
strain Newman (P=0.0019), PS80 (P=0.0070) or LAC
(P=0.0068) (Fig. 6), indicating that the efficacy of antibody to
the IsdB antigen was still manifest in a setting wherein the
antibodies to the surface carbohydrate antigens would not be
expected to be active.
Passive immunization with anti-CP5-ClfB protects mice
against S. aureus nasal colonization
Previous studies demonstrated that a S. aureus clfB mutant
showed reduced nasal carriage compared to the parent strain [16]
and antibody to ClfB reduced levels of bacterial colonization in the
mouse nose. Because ClfB is maximally detected on the
staphylococcal cells only during the logarithmic phase of growth
Figure 4. Passive immunization with 9GlcNH2-Hla antibodies in a murine model of S. aureus pneumonia. (a) Mice were vaccinated i.n
with 20 ml of 9GlcNH2-Hla antisera or NRS 24 h and 4 h prior to infection with indicated S. aureus strains (4610
8 CFU/mouse). Bacterial burden was
recorded 24 h post-infection. Points indicate cfu/lung of individual mice, lines the group median; p values: Mann-Whitney test. (b) Kaplan–Meier
survival curve of 4 week old FVB mice vaccinated i.n with 20 ml of 9GlcNH2-Hla antisera or NRS 24 h and 4 h prior to infection with indicated S. aureus
strains (6610
8 CFU/mouse). Survival was monitored at least twice a day over a 5 day period and data analyzed using the Log-rank test to derive the p
values.
doi:10.1371/journal.pone.0046648.g004
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r Newman grown in
TSB to mid-log phase (OD600 nm of 0.5). Passive immunization
experiments administering polyclonal anti-CP5-ClfB 14 h prior to
inoculation with S. aureus Sm
r Newman significantly reduced the
CFU/nose compared to the mice receiving NRS (P=0.0011)
(Fig. 7), indicating that conjugation of ClfB to CP5 retained its
ability to induce colonization-inhibition antibodies. Attempts to
determine the efficacy of antibody to ClfB in reducing nasal
colonization by the other strains were thwarted by the inability of
Figure 5. Protective efficacy of 9GlcNH2-Hla, CP5-ClfB or CP8-IsdB antibodies against skin abscess infection by S. aureus. Antisera
(300 ml) were administered IP 24 h and 4 h prior to injection of skin with indicated S. aureus strain mixed with 60–87 mm dextran beads. Points
indicate cfu/individual abscess, lines the group median, (A) Results following immunization with 9GlcNH2-Hla antisera or NRS and challenge with S.
aureus Newman, PS80 or USA 300 LAC. (B) Results following immunization with CP5-ClfB antisera or NRS and challenge with S. aureus Newman, or
USA300 LAC. (C) Results following immunization with CP8-IsdB antisera or NRS and challenge with S. aureus Newman, PS80 or USA300 LAC; (p values
determined by Mann-Whitney test.
doi:10.1371/journal.pone.0046648.g005
Figure 6. Protective efficacy of 9GlcNH2-Hla, CP5-ClfB or CP8-
IsdB combining antibodies against S. aureus skin abscess
formation. Mice were passively immunized with 300 ml of antisera
mixed together and administered 24 h and 4 h prior to challenge with
indicated S. aureus strains mixed with 60–87 mm dextran beads. The
CFU/abscess recovered in mice vaccinated show a significant reduction
compared to the NRS group (p values determined by Mann-Whitney
test).
doi:10.1371/journal.pone.0046648.g006
Figure 7. Passive immunization CP5-ClfB antibodies reduced S.
aureus Newman nasal colonization. Mice were vaccinated IP with
300 ml of antisera 14 h prior to inoculation with 10
9 CFU. Dots indicate
the number of CFU/nose of individual mice, lines the group median, P
value by Mann-Whitney U test.
doi:10.1371/journal.pone.0046648.g007
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a 5-day period.
Discussion
Currently, the lack of requisite knowledge of effective acquired
immunity in humans to S. aureus complicates the endeavor to
design and evaluate an appropriate vaccine for this pathogen. As a
result both laboratory investigations [4,10,16,17,18,20,50,51] and
human clinical trials [3,6,52] have evaluated vaccines based
primarily on efficacy of active or passive immunization in animals
and supported by some correlative in vitro functional assays such
as OPK or inhibition of adherence to host tissues. To date, human
studies have only been carried out by vaccination against single
bacterial components and not utilized multivalent component
vaccines, which have been proposed to potentially be more
effective vaccines against microbial pathogens. However appealing
this concept is, nonetheless there are no data to indicate if such an
approach is likely to be feasible for S. aureus due to the
aforementioned lack of knowledge of the molecular and/or
cellular basis for effective human immunity to this pathogen.
Thus, at this stage, production and characterization of antigenic
components for a S. aureus vaccine is still based on empirical
approaches. Therefore, we chose to incorporate into our candidate
vaccine the three known major surface polysaccharides, PNAG,
CP5 and CP8, as representative of antigens that have been used
successfully in other bacterial vaccines [53,54], and three proteins,
non-toxic Hla, IsdB and ClfB, due to support from other studies of
protective efficacy in animal settings [5,16,21]. In addition, PNAG
was tested because of the range of bacterial pathogens that
produce this antigen, making it an attractive vaccine candidate
due to its potential to protect against multiple, important human
pathogens [11,12,55,56,57,58,59]. Of primary concern was
whether the use of Hla (H35L), ClfB N region (amino acids 44
to 542) or IsdB as carrier proteins for carbohydrate antigens would
result in induction of antibodies active against the native proteins
expressed by S. aureus.
The results reported indicate that individual antisera raised in
rabbits had good OPKA targeting the CP and PNAG antigens and
also reduced infection in mouse models of pneumonia, skin
abscesses, and in the case of antibody to CP5 and ClfB, nasal
colonization. Thus, all three of the carrier proteins used showed
themselves capable of promoting antibody to polysaccharide
antigens when incorporated into conjugate vaccines. Unfortunate-
ly, we also found that use the 9GlcNH2 glycoform of PNAG to
induce antibody to this antigen, as well as use of different carrier
proteins, did not abrogate the interference in OPK when the
antibodies raised to PNAG and CP were both present, as observed
previously [15]. Given that the prior results demonstrating
interference were obtained using an 85% deacetylated glycoform
of native, high molecular-weight PNAG [15] in a conjugate
vaccine, we had hoped that use of a smaller molecule completely
devoid of acetates for immunization might overcome this
interference, but this was not the case. Also, there was some
expectation using different carrier proteins might have induced
antibodies to PNAG and/or CP antigens with non-interfering
idiotypes, as a recent study [60] showed that the specificity of
MHC class II antigen presentation by carbohydrate-reactive B
cells of carbohydrate-protein conjugate vaccines to responsive
helper T cells was dependent upon the linkage of the polysaccha-
ride and the carrier protein. Interference between antibody to
PNAG and CP antigens was observed only when antisera were
present at specific ratios because some sera have a high enough
OPKA such that the activity can only inhibited when the
interfering serum is diluted to achieve specific ratios with the
competitor antisera. However, in considering how this might
impact use of both PNAG and CP antigens in a human vaccine,
the variability in individual responses likely would mean that many
humans could produce antibody to PNAG and S. aureus CP
antigens in proportions resulting in interference with the individual
opsonic and protective activity. We have documented that this
phenomenon occurs in serum from a high proportion of humans
recovering from S. aureus bacteremia [15].
In terms of immunity elicited to the proteins, we found that use
of the non-toxic Hla (H35L) [19] protein as a carrier for the
9GlcNH2 oligosaccharide of PNAG led to antibodies that
neutralized the hemolytic effect of native Hla in vitro and reduced
the bacterial burden of three S. aureus strains in a murine
pneumonia model. S. aureus alpha toxin is a pore-forming
cytotoxin, and previous studies indicated that an Hla (H35L)
vaccine protected against lethal staphylococcal pneumonia [61],
reduced the size of skin lesions and prevented dermonecrosis in
mice infected subcutaneously with the epidemic USA 300 LAC
community associated MRSA strain [62]. Our data indicate that
Hla (H35L) is a good carrier protein for a conjugate vaccine
because it retained its desirable immunogenic properties after
conjugation to 9GlcNH2 and also there was an improved
protective effect when antibody to both PNAG and Hla were
administered to mice challenged with WT S. aureus compared to
mice given this same serum and challenged with PNAG-negative
S. aureus, wherein only the antibody to Hla would be effective in
mediating protective effects.
IsdB is broadly expressed among diverse S. aureus clinical
isolates and is highly conserved (94–100%) in both methicillin
resistant and susceptible clinical isolates. The immunogenic role of
this protein has been widely investigated. IsdB strongly induces an
increase in antibody titers and is protective against abscess
formation and lethal intravenous challenge [4,63]. Here we found
that conjugating CP8 to IsdB elicited antibodies that recognized
native IsdB present on S. aureus grown in a low, but not high, iron
medium and these antibodies also reduced the CFU/skin abscess
caused by all three S. aureus strains tested, including two strains not
producing CP8. When the antisera raised to the three surface
polysaccharide-protein conjugates were all combined and admin-
istered to mice, the levels of bacteria in skin abscesses were still
reduced, indicative of maintenance of the protective efficacy of
antibody to IsdB in a setting where the antibodies to the
carbohydrate antigens would be expected to lose protective
efficacy due to their mutual interference. While this result might
recommend IsdB as a good component of a S. aureus vaccine, the
recent failure of this antigen as a monovalent vaccine in a clinical
trial in cardiothoracic surgery patients (Merck, Intercell press
release, http://www.merck.com/newsroom/news-release-
archive/research-and-development/2011_0608.html, 8 June
2011), which included some suggestions of a greater, but non-
significant, degree of adverse events in the IsdB-immunized
individuals, likely means that further studies of this antigen in
humans will be difficult to justify and undertake [64].
Clumping factor B (ClfB) has been determined to be an
attractive candidate to include in a vaccine for humans as animal
studies indicate antibody to this antigen reduces S. aureus nasal
colonization [16]. S. aureus binds to mouse cytokeratin 10, and
antibody to ClfB impairs nasal colonization, which can diminish
the risk of staphylococcal infection [16]. Here we found that a
CP5-ClfB conjugate vaccine induced antibodies that inhibited S.
aureus Newman nasal colonization in mice, indicating that the
conjugation of ClfB to CP5 retained epitopes capable of eliciting
colonization-interfering antibody. The contribution of CP5
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able to obtain chronic nasal colonization in mice with a non-CP5
strain.
Overall, our findings indicate that the S. aureus surface
polysaccharides PNAG, CP5 and CP8, when conjugated to carrier
proteins Hla, IsdB or ClfB, can induce high titers of polysaccharide-
specific opsonic antibody and protein specific functional antibody
that individually reduced experimental S. aureus skin infection,
pneumonia and nasal colonization. However, use of the synthetic
oligosaccharide glycoform of PNAG and different carrier proteins
did not overcome the interference in OPKA engendered when
antibodies to PNAG are combined with antibody to either CP5 or
CP8 [15]. This finding further indicates that a vaccine containing
both S. aureus CP antigens and PNAG may be problematic to
develop.The implications of this finding might be that if antibody to
the GlcNH2-glycoform of PNAG is truly protective against the
range of pathogens producing this antigen as a surface molecule,
then vaccines raising antibody to CP antigens could interfere with
the protective efficacy of antibody to PNAG. Alternately, if PNAG
does not have good safety or protective efficacy in humans, then
antibody to S. aureus CP antigens, potentially along with other
vaccine components, may have high potential as a vaccine.
Currently, a fully human MAb to PNAG is in phase II clinical
trials (http://clinicaltrials.gov/ct2/show/NCT01389700?term=
SAR279356&rank=1), and vaccines containing CP5 and CP8
conjugates along with other components are also in early clinical
trials (http://clinicaltrials.gov/ct2/show/NCT01364571?term=
staphylococcus+aureus+%26+vaccine&rank=2 and http://
clinicaltrials.gov/ct2/show/NCT01160172?term=staphylococcus+
aureus+%26+vaccine&rank=10), results from which may help
ascertain the utility of these antigens as components of a S. aureus
vaccine [65]. Finally, while our study focused on the role of
antibodiesand useofpassiveimmunitytoevaluatepotentialS.aureus
vaccines, there are now some data indicating a possible role for T-
cell based immunity [66,67], particularly involving the TH17
pathway, in immunity to S. aureus infection [7]. However, it is likely
most otherwise healthy humans have naturally-acquired T-cell
based immunity to S. aureus that is contributing to resistance to
infection, since individuals that lose such immunity become more
susceptibletoS.aureusinfections(reviewedin[7]).Also,patientswith
chronic granulatomatous disease who have phagocytes unable to
mediatebacterialkillingduetodeficienciesinthereduced NADPH-
oxidasesystemhave ahighrateofS.aureusinfections[68],indicating
that classic opsonic killing, a process augmented by antibody and
complement deposition ontothebacterialsurface,playsa keyrole in
human resistance to this pathogen. Thus, it is most likely that
antibody mediated OPK will play an important role in vaccination
against S. aureus infection, indicating that successful vaccine
development will need to incorporate antigens capable of inducing
potent OPK.
Supporting Information
Figure S1 Purity of indicated recombinant protein used
to produce conjugate vaccines. By analysis of the scanned
gels all recombinant proteins were .95% pure.
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